The company specializes in the acquisition and resolution of disputed financial claims and arbitration cases, while also providing personal and business loans and trading in equity securities.
The company lacks a durable competitive advantage as evidenced by highly volatile revenues and deeply negative average net margins. While it claims expertise in legal claim resolution, the financial results show no persistent pricing power or scale benefits, with returns on capital consistently below the cost of capital.
Capital has been deployed into high-risk litigation assets and partnership firms with limited liquidity, alongside significant related-party transactions. The track record is poor, characterized by inconsistent profitability and a lack of clear value creation for minority shareholders.
The business collapsed as the subjective valuation of litigation assets finally met reality, leading to massive write-downs of the inventory. The capital tied up in illiquid partnership firms remained trapped by legal disputes, while the promoter continued to drain the remaining cash through tax reimbursements and rent. As independent directors fled the board, the lack of a durable competitive advantage was exposed, leaving minority shareholders with a hollow shell of a company that never earned its cost of capital.
RichFakir rates Futuristic Solutions Ltd's business quality as poor — 22/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Futuristic Solutions Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Futuristic Solutions Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Futuristic Solutions Ltd's fair value is about ₹12 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →